"Stem Cell Genome Modification Laboratory"
This laboratory was established as part of a scientific research project supported with a monetary grant awarded by the Government of the Russian Federation under a grant competition designed to provide governmental support to scientific research projects implemented under the supervision of the world's leading scientists at Russian institutions of higher learning, research institutions of the governmental academies of sciences and governmental research centers of the Russian Federation (Resolution of the RF Government No.220 of April 9, 2010).
Host institution of higher learning:
State educational institution of higher professional education "Puschino State University"
Scientific research area:
Medical sciences and technologies
To look for new approaches to the development of medications based on directional genome modification.
Key project objectives:
1. To create a stem cell genome modification laboratory and to implement the most advanced standard operating procedures on experimental animals into its practices;
2. To prepare lines of embryonic stem cells of mice and to research the mechanisms responsible for the development of atherosclerosis;
3. To modify all encoding sequences of the mouse genome for the purpose of their conventional or conditional knockout;
4. To engage undergraduate and graduate students in research activities and train young researchers specializing in modification of mammalian genome for the purpose of identifying new targets for medications.
Anticipated project outputs:
1. The project will help develop the technological base for the Russian program of production of new pharmaceuticals;
2. The project will help create Russian intellectual property in the field of biotechnologies.
Leading scientist's full name: Kotelevtsev, Yuri Vasilyevich
Candidate of chemical sciences
Leading Researcher at the Cardiological Center of the Royal Institute of Medical Research of the University of Edinburg (Scotland).
Field of scientific interests:
1. Molecular and cellular mechanisms responsible for hypertension and atherosclerosis.
2. Transgenic models of cardiovascular diseases.
3. Genetically modified mice as a platform for the development of new pharmaceuticals.
- Several patents for a method identifying one's susceptibility for hypertension;
- A patent for the discovery of several versions of the Angiotensinogen and determination of one's susceptibility to hypertension based thereupon;
- A patent for the discovery of antihypertensive compounds (1-alkyl-2-alkylcarbamoyl-glycerins) and their production methods.